Literature DB >> 16301188

Assessment of fracture risk: who should be treated for osteoporosis?

M van der Klift1, C D E de Laet, H A P Pols.   

Abstract

The clinical significance of osteoporosis arises from the fractures that occur. Of these, the hip fracture in particular is associated with high morbidity, mortality and socio-economic costs. The primary goal of osteoporosis treatment is fracture prevention. In this chapter we try to answer the question of how to assess fracture risk and how to identify those above a given risk threshold so that treatment can be given to those in whom fractures can be prevented (cost-) effectively. At first, the two main strategies for fracture prevention--population screening and case finding--are discussed. Then a fracture risk assessment score, based on easily identifiable clinical risk factors, is proposed. This clinical risk factor analysis can guide the decisions whether additional bone assessment is relevant and whether treatment should be started. Finally, we advocate that absolute fracture risk is important for communication with the patient about the decision whether or not to initiate treatment.

Entities:  

Mesh:

Year:  2005        PMID: 16301188     DOI: 10.1016/j.berh.2005.06.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  10 in total

1.  Validation of the Cummings' risk score; how well does it identify women with high risk of hip fracture: the Tromsø Study.

Authors:  Luai A Ahmed; Henrik Schirmer; Vinjar Fønnebø; Ragnar M Joakimsen; Gro K Berntsen
Journal:  Eur J Epidemiol       Date:  2006-11-22       Impact factor: 8.082

2.  Risk factors for hip fracture in older home care clients.

Authors:  Paul Stolee; Jeff Poss; Richard J Cook; Kerry Byrne; John P Hirdes
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-02-05       Impact factor: 6.053

3.  Assessment of determinants for osteoporosis in elderly men.

Authors:  S Scholtissen; F Guillemin; O Bruyère; J Collette; B Dousset; C Kemmer; S Culot; D Crémer; H Dejardin; G Hubermont; D Lefebvre; V Pascal-Vigneron; G Weryha; J Y Reginster
Journal:  Osteoporos Int       Date:  2008-11-15       Impact factor: 4.507

4.  The gender- and age-specific 10-year and lifetime absolute fracture risk in Tromsø, Norway.

Authors:  Luai A Ahmed; Henrik Schirmer; Ashild Bjørnerem; Nina Emaus; Lone Jørgensen; Jan Størmer; Ragnar M Joakimsen
Journal:  Eur J Epidemiol       Date:  2009-05-30       Impact factor: 8.082

5.  The Rotterdam Study: 2012 objectives and design update.

Authors:  Albert Hofman; Cornelia M van Duijn; Oscar H Franco; M Arfan Ikram; Harry L A Janssen; Caroline C W Klaver; Ernst J Kuipers; Tamar E C Nijsten; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2011-08-30       Impact factor: 8.082

6.  Influence of insurance benefit criteria on the administration rate of osteoporosis drugs in postmenopausal females.

Authors:  Jae Hyup Lee; Ye-Hyun Lee; Seoung-Hwan Moon; Yil-Seob Lee
Journal:  Clin Orthop Surg       Date:  2014-02-14

7.  [Overdiagnosis in women's health: The case of osteoporosis].

Authors:  Elena Cardona Corrochano; Ana Pereira Iglesias; David Fraile Navarro; Alberto López García Franco
Journal:  Aten Primaria       Date:  2018-11       Impact factor: 1.137

8.  The Rotterdam Study: 2010 objectives and design update.

Authors:  Albert Hofman; Monique M B Breteler; Cornelia M van Duijn; Harry L A Janssen; Gabriel P Krestin; Ernst J Kuipers; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Johannes R Vingerling; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2009       Impact factor: 8.082

9.  [Osteoporosis: How, when and how far].

Authors:  Alberto López García-Franco
Journal:  Aten Primaria       Date:  2016-04       Impact factor: 1.137

10. 

Authors:  Alberto López García-Franco; José Antonio Baeyens Fernández; Emilia Bailón Muñoz; M José Iglesias Piñeiro; Isabel Del Cura González; Amparo Ortega Del Moral; Jacinta Landa Goñi; Pablo Alonso Coello; Lorenzo Arribas Mir
Journal:  Aten Primaria       Date:  2018-05       Impact factor: 1.137

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.